Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 1024 of 6351
-
Light-Activated therapy could offer Surgery-Free route for early anal cancer
Disease control CancelledThis is a phase I dose escalation study of photodynamic therapy (PDT) for the treatment of patients with pre-malignant tumors and superficial microinvasive disease of the anal canal and/or perianal skin. All subjects (a maximum of 12) will be given the photosensitizer ALA orally …
Phase 1 • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Family history as a shield: can culturally tailored guidance cut cancer risk?
Prevention CompletedThis study evaluated a culturally and linguistically tailored cancer prevention program delivered by trained Chinese American community health workers to Chinese American adults in Texas. The program focused on breast, colorectal, gastric, liver, and lung cancers and used family …
Sponsor: Texas A&M University • Aim: Prevention
Last updated Aug 16, 2026 00:00 UTC
-
Can a Personality-Targeted program keep teens off drugs?
Prevention OngoingDespite having made some strides with respect to reducing adolescent drinking rates, illicit substance use and substance use disorders (SUDs) remain significantly above national targets for health promotion and disease prevention in Canada and the United States. Now, more than ev…
Sponsor: St. Justine's Hospital • Aim: Prevention
Last updated Jun 27, 2026 12:24 UTC
-
Blood test may spot hidden gallbladder cancer in gallstone patients
Diagnosis CompletedWe have observed that the serum levels of certain metabolites differ between Chilean patients with gallbladder cancer and those with gallstone disease. Based on these discovery results, we selected ten candidate metabolites based on the smallest p-values among metabolites exhibit…
Sponsor: Centre Paul Strauss • Aim: Diagnosis
Last updated Aug 06, 2026 00:00 UTC
-
Gene-Guided drug cocktail shows promise for Tough-to-Treat gynaecological cancers
Disease control OngoingATARI trial tests the ATR inhibitor drug ceralasertib (AZD6738) alone and in combination with either a PARP inhibitor drug called olaparib, or an anti-PD-L1 immunotherapy called durvalumab (MEDI4736) in patients with relapsed gynaecological cancers to assess the response in group…
Phase 2 • Sponsor: Institute of Cancer Research, United Kingdom • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New vaccine aims to shield transplant patients from deadly virus
Vaccine OngoingThis phase II trial studies how well Triplex vaccine works in preventing cytomegalovirus (CMV) infection in patients undergoing a hematopoietic stem cell transplantation. CMV is a virus that may be carried for life and does not cause illness in most healthy individuals. However, …
Phase 2 • Sponsor: City of Hope Medical Center • Aim: Vaccine
Last updated Jun 27, 2026 07:57 UTC
-
New pill shows promise for treating spinal arthritis in large trial
Disease control CompletedThis protocol includes 2 standalone studies with randomization, data collection, analysis and reporting conducted independently. The main objectives of this protocol are: * To evaluate the efficacy of upadacitinib compared with placebo on reduction of signs and symptoms in adul…
Phase 3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Could donor stem cells help lungs heal in ARDS?
Disease control CompletedThis is a Phase 2b, randomized, double-blind, placebo-controlled, multi-center study to assess the safety and efficacy of a single dose of Allogeneic Bone Marrow-derived Human Mesenchymal Stromal Cells (hMSCs) infusion in patients with Acute Respiratory Distress Syndrome (ARDS). …
Phase 2 • Sponsor: Michael A. Matthay • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New hope for nigerian women with aggressive breast cancer: targeted therapy trial underway
Disease control OngoingThis is a one stage phase II study with a single arm design. It will be conducted in HER-2 positive breast cancer patients in Nigeria who are chemotherapy/hormonal treatment naive.
Phase 2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
A shot that could shield healthcare workers from a silent killer
Prevention CompletedHepatitis B virus (HBV) has infected over one third of the world's population; of these about 350 million go on to be chronic carriers. Infection with HBV can be self-limiting depending on age and immunity status of the infected person. Acute infection with HBV is cleared within …
Phase 4 • Sponsor: Centre for Infectious Disease Research in Zambia • Aim: Prevention
Last updated Aug 12, 2026 00:00 UTC
-
Can an inhaled protein save lungs in Alpha-1? new trial aims to find out
Disease control Stopped earlyThe goal of this clinical trial is to learn if AAT for inhalation, at a dose of 80 mg/day can slow the progression of lung disease in people who have lung disease caused by severe genetic deficiency in Alpha 1 Antitrypsin (AATD). The main question it aims to answer is: • Can da…
Phase 3 • Sponsor: Kamada, Ltd. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can a tiny sensor inside a vein predict heart failure crises?
Disease control OngoingFirst in Human Clinical Investigation of the FIRE1 Device/System to evaluate the feasibility and safety of implanting the FIRE1 system in up to 50 stable HF patients.
Sponsor: Foundry Innovation & Research 1, Limited (FIRE1) • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New hope for Tough-to-Treat leukemia: experimental drug DFP-10917 tested in Late-Stage trial
Disease control Stopped earlyPhase III, multicenter, randomized study with two arms (1:1 ratio) enrolling patients with AML relapsed/refractory after 2, 3, or 4 prior induction regimens: Experimental arm: DFP-10917 14-day continuous intravenous (IV) infusion at a dose of 6 mg/m²/day followed by a 14-day res…
Phase 3 • Sponsor: Delta-Fly Pharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New CT scanner aims to replace invasive heart tests for High-Risk patients
Diagnosis CompletedCardiac catheterization with invasive coronary angiography is the gold standard for determining the presence or absence of significant coronary heart disease (CHD). However, cardiac catheterization is costly and, as an invasive procedure, it is associated with some risk of advers…
Sponsor: Johns Hopkins University • Aim: Diagnosis
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo aims to tame myeloma in older patients without harsh chemo
Disease control CompletedThis is a Phase II study of daratumumab based therapies for older adults with multiple myeloma.
Phase 2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Could two weeks of radiation be enough for breast cancer?
Disease control OngoingPatients with Stage 0 ductal carcinoma in situ (Tis (DCIS), Stage T1-T2, lymph node negative(N0) breast cancers will be randomized to receive whole breast radiotherapy with a concomitant boost to the tumor bed over 15 fractions (Arm 1, standard) versus 10 fractions (Arm 2, experi…
Phase 3 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Second-Chance CAR-T: could Off-Spec cells still fight cancer?
Disease control Recruiting nowThis study will evaluate the safety of tisagenlecleucel that is out of specification( OOS) for release as commercial product. Specifically, this study will evaluate the safety of CTL019 in the patients treated within the approved label by Japan Health Authority in Part 2. Only fo…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New stem cell therapy aims to tame transplant complications
Disease control OngoingThis study will evaluate the safety, tolerability, and efficacy of Orca-T, an allogeneic stem cell and T-cell immunotherapy biologic manufactured for each patient (transplant recipient) from the mobilized peripheral blood of a specific, unique donor. It is composed of purified he…
Phase 1 • Sponsor: Orca Biosystems, Inc. • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New hope for aggressive breast cancer: two chemo cocktails face off in clinical trial
Disease control Recruiting nowThis is a multi-center , open-lable clinical trial. Triple-negative breast cancer (TNBC) is a term applied to breast cancer cases that have \<1% expression of the estrogen receptor (ER) and the progesterone receptor (PR) and do not over express HER2. TNBC is diagnosed in 15-20% o…
Phase 2 • Sponsor: Hebei Medical University Fourth Hospital • Aim: Disease control
Last updated Jun 26, 2026 15:49 UTC
-
New trial tests which chemo combo best shrinks tough breast tumors
Disease control Recruiting nowThis is a multicenter, open, randomized, comparison study. Triple-negative breast cancer (TNBC) is a term applied to breast cancer cases that have \<1% expression of the estrogen receptor (ER) and the progesterone receptor (PR) and do not over express HER2. Neoadjuvant therapy i…
Phase 2 • Sponsor: Hebei Medical University Fourth Hospital • Aim: Disease control
Last updated Jun 26, 2026 16:12 UTC